Claritas Pharmaceuticals, Inc.
CLAZF
$0.00
$0.000.00%
OTC PK
| 09/30/2021 | 06/30/2021 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -6.38% | 245.28% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -6.38% | 245.28% | |||
| Operating Income | 6.38% | -245.28% | |||
| Income Before Tax | 114.32% | 54.48% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 114.32% | 45.07% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 109.31% | 15.51% | |||
| EBIT | 6.38% | -245.28% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 108.76% | 30.38% | |||
| Normalized Basic EPS | 113.56% | -475.61% | |||
| EPS Diluted | 108.76% | 30.38% | |||
| Normalized Diluted EPS | 113.56% | -475.61% | |||
| Average Basic Shares Outstanding | 6.00% | 21.36% | |||
| Average Diluted Shares Outstanding | 6.00% | 21.36% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||